BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress

  La Jolla Pharmaceutical Company reported financial results for the three and nine months ended September 30, 2017 and highlighted recent corporate progress.

  October 26, 2017

   · 

  8 min read
• Breakthrough Medical and Pharmaceutical Funding Awarded to Consortium That Partners Avita Medical With 20 Other Organisations Across Australia

  Regenerative skin company Avita Medical is delighted to be part of Accelerating Australia, a consortium that will inject up to $2 million into a breakthrough innovation project designed to commercialise big ideas.

  October 26, 2017

   · 

  5 min read
• Biotech Beach

  Lin BioScience Receives U.S. FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease

  Lin BioScience announced today that the FDA has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease.

  October 26, 2017

   · 

  2 min read
• Business

  MorphoSys to Host Q3 2017 Conference Call on November 7, 2017

  MorphoSys AG will publish its first nine months’ 2017 results on November 7, 2017 at 7:00 am CET.

  October 26, 2017

   · 

  1 min read
• Business

  Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., As Chief Development Officer and Chief Medical Officer

  Topas Therapeutics GmbH (Topas) announced the appointment of Rupert Sandbrink, M.D., Ph.D., to the newly created position of Chief Development Officer and Chief Medical Officer.

  October 26, 2017

   · 

  3 min read
• Genetown

  VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares

  VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering.

  October 26, 2017

   · 

  5 min read
• Business

  Harvard Bioscience Appoints Katherine Eade and Thomas Loewald to the Board of Directors

  The new hires were effective October 24, 2017.

  October 26, 2017

   · 

  2 min read
• Business

  Vital Therapies Announces Third Quarter 2017 Financial Results

  Vital Therapies announced results for the third quarter ended September 30, 2017.

  October 26, 2017

   · 

  8 min read
• BioCapital

  Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month

  Compugen announced it will present two posters with new data on COM701, the Company’s first-in class immuno-oncology therapeutic antibody candidate targeting PVRIG, and COM902.

  October 26, 2017

   · 

  3 min read
• Pharm Country

  Misonix Cites Significant Healthcare Cost Savings Using BoneScalpel in Bone Removal Procedures

  Misonix cited data that demonstrated the use of BoneScalpel can produce up to a 40% cost reduction in biologic grafting material spend in spinal fusion procedures.

  October 26, 2017

   · 

  4 min read